ProMIS Neurosciences Inc. (NASDAQ:PMN) rose 6% on Monday after new research findings bolstered confidence in the company’s biomarker-focused approach to Alzheimer’s disease drug development.
The company said a peer-reviewed paper published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions found that plasma phosphorylated tau (pTau) biomarkers may serve as reliable early indicators of clinical benefit in Alzheimer’s therapies. According to ProMIS, the analysis showed that treatment-driven changes in plasma pTau at six months had a strong correlation with patient outcomes assessed at 12 months.
The study—conducted by Pentara Corporation with support from ProMIS scientists—showed that biomarker changes were both earlier and more pronounced than clinical measures, with effect sizes roughly 2.6 times larger.
“This publication provides important validation of the strategy we have adopted at ProMIS which is to use highly sensitive plasma pTau biomarkers as a central pillar of our ongoing Phase 1b AD clinical trial,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences.
The findings reinforce the rationale behind the company’s ongoing PRECISE-AD study evaluating PMN310, its lead antibody designed to selectively neutralize toxic amyloid-beta oligomers without interacting with monomers or plaque. ProMIS reiterated that an interim readout is expected in the second quarter of 2026.
The company added that the new research indicates that proof-of-concept studies using plasma pTau as a primary endpoint might be adequately powered with as few as 100 participants, potentially enabling smaller and more efficient clinical trials.